Zika Virus-Infected Monocyte Exosomes Mediate Cell-to-Cell Viral Transmission

Pedro Pablo Martínez-Rojas1, Verónica Monroy-Martínez1, Lourdes Teresa Agredano-Moreno2

  • 1Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México 04510, México.

Cells
|January 22, 2024
PubMed

Insights

Zika virus (ZIKV) can spread through exosomes released by infected monocytes. These exosomes facilitate ZIKV transmission, infection, and cell activation, offering a new understanding of severe Zika disease.

Area of Science:

  • Virology
  • Immunology
  • Cell Biology

Background:

  • Zika virus (ZIKV) is an arthropod-borne virus causing severe neurological and developmental disorders.
  • Monocytes are key targets for ZIKV, and their response involves releasing exosomes.
  • Exosomes play a role in intercellular communication and immune evasion during viral infections.

Purpose of the Study:

  • To investigate the role of exosomes derived from ZIKV-infected monocytes in viral transmission.
  • To determine if these exosomes can mediate cell-to-cell spread of ZIKV.

Main Methods:

  • Isolation of exosomes from ZIKV-infected human monocytes (Mø exo ZIKV) using differential ultracentrifugation.
  • Characterization of exosomes via nanoparticle tracking analysis, transmission electron microscopy, and surface marker detection (CD63, CD81, TSG101, Alix).
  • Purification of exosomes and assessment of their infectivity and impact on recipient cells.

Main Results:

  • Mø exo ZIKV were confirmed to contain ZIKV RNA and E/NS1 proteins.
  • Exposure of naïve cells to Mø exo ZIKV promoted viral transmission and infection.
  • Interaction with Mø exo ZIKV led to recipient cell differentiation and activation.

Conclusions:

  • Monocyte-derived exosomes serve as an efficient pathway for ZIKV cell-to-cell transmission.
  • Understanding this transmission route is crucial for ZIKV pathogenesis research.
  • These findings can inform the development of novel ZIKV vaccines and therapeutics.